Lupin Share Price Trading Near its Current Month High

The 7th Wonder of Pharma Sector

Lupin Limited is India’s seventh largest Pharmaceutical Company in terms of market

capitalization and the fifth largest in the United States by prescription led market share. The

advent of the 21st century ushered the need for companies with solid values and strong vision

in the pharmaceutical industry. Following the traditional path of economics where demand

creates supply, Lupin Ltd. has emerged as the best fit with a vision to excel beyond the realm of

economic cycles, competition, and eventually beyond lifetimes and generations. As the

Founding Chairman cites, that it is the ‘Lupin Spirit’ which has aided the Pharma Giant innovate

and deliver excellent performance consistently year after year. Unending innovation and

competitive edge has kept Lupin a step ahead of its peers in the modern day business

environment.

A Global Player

A company that envelopes the entire pharmaceutical value chain, Lupin’s Indian branch caters

to Chronic disease and Lifestyle therapies in the areas of Cardiology, Neurology and Diabetes.

Its European equivalent focuses on opportunities and developments in Oral Contraceptives,

Ophthalmology and Dermatology. In the US, the company works on Pediatric segments and CVS

where 28 out of its 77 products dominate the market.

The India Story

India plays an intrinsic role in the ambitious growth plans of Lupin by contributing as much as

24 per cent of the Company’s total global revenues. The Indian markets have been the vital cog

in Lupin’s resilient revenue figures of Rs. 30,295 million which reflected an impressive growth of

20.5 per cent in FY15 against an industrial growth of 12.1 per cent. Currently, Lupin share price

stands at Rs. 1,530.90. Over the last four years Lupin’s CAGR stood at 18 per cent where

Chronic therapies contributed to 66 per cent of the total revenues generated in the Indian

subcontinent. The company continues to rule the Anti- TB market and is currently the third

largest player in Cardiology and Anti Asthma segments.

Reading between Price and Product

In FY15, Lupin initiated phase-1 clinical studies for 4 of its products and filed 18 ANDAs

including 5 First-to-File products with USFDA. Later on, the company received approvals from

FDA for 12 of its ANDAs while the cumulative ANDA stands at 210.

The Pharma Giant appears all set to make an everlasting impression on the global arena with

ICRA assigning “ICRAA1+” for Lupin’s short term credit facilities.

Disclaimer The investment advice or guidance provided by way of recommendations, reports or other ways are solely the personal views of the research team. Users are advised to use the data for the purpose of information and rely on their own judgment while making investment decision. Dynamic Equities Pvt. Ltd - SEBI Investment Advisory Reg. No.: INA300002022 Disclosure Dynamic Equities Pvt. Ltd. is a member of NSE, BSE, MCX SX and a DP with NSDL & CDSL. It is also engaged in Investment Advisory Services and Portfolio Management Services. Dynamic Commodities Pvt. Ltd., associate company, is a member of MCX & NCDEX. We declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered. SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise letters or levied minor penalty on for certain operational deviations. Answers to the Best of our knowledge and belief of Dynamic/ its Associates/ Research Analyst: DYNAMIC/its Associates/ Research Analyst/ his Relative:

Do not have any financial interest / any actual/beneficial ownership in the subject company.

Do not have any other material conflict of interest at the time of publication of the

research report

Have not received any compensation from the subject company in the past twelve months

Have not managed or co-managed public offering of securities for the subject company.

Have not received any compensation for brokerage services or any products / services

or any compensation or other benefits from the subject company, nor engaged in market making activity for the subject company

Have not served as an officer, director or employee of the subject company

Article Written By: Shivaji Ghata